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Abstract This article presents a review of conservative
therapies for plantar fasciitis pain reduction with a discus-
sion of steroid therapy risks. The therapies reviewed include
orthoses, stretching, extracorporeal shockwave, BTX-A, and
corticosteroid injection/iontophoresis. These modes were
included based on the availability of double blinded ran-
domized controlled trials. We noted the following ﬁndings.
Orthoses, regardless of type, can improve pain levels.
Plantar stretching shows limited short-term beneﬁt
(1 month), but can reﬂect signiﬁcant long-term improve-
ment (10 months). Extracorporeal shockwave therapy shows
equivocal beneﬁt with some studies showing signiﬁcant
improvement and others showing none. Although BTX-A
injections were the least studied, signiﬁcant pain improve-
ment was demonstrated in the short and long term. Steroid
injection/iontophoresis showed signiﬁcant improvement
in the short term (1 month). Steroid therapy, when coupled
with plantar stretching, can provide efﬁcacious pain relief;
however, steroid injections should be combined with
ultrasound monitoring to reduce complications.
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Plantar fasciitis is a common foot disorder responsible for
approximately one million physician visits per year [1].
While there are a plethora of management techniques for
plantar fasciitis, there are none that are presented as a
deﬁnitive technique. In addition, the etiology of plantar
fasciitis is not well understood [2]. Accordingly, this article
will focus on a variety of conservative therapies with a
follow-up focus on steroid injections and the risks thereof.
Anatomy
The plantar fascia is synonymous with the deep fascia of
the sole of the foot. The plantar fascia is comprised of
pearly white longitudinally organized ﬁbers. It begins at the
medial tuberosity of the calcaneus where it is thinner and
extends into a thicker center portion. This thicker portion is
ﬂanked by thinner lateral and medial portions. The thicker
central portion of the plantar fascia then extends into ﬁve
bands surrounding the digital tendons (Fig. 1)[ 2, 3].
Plantar fasciitis classically presents histologically with
‘‘degenerative changes in the plantar fascia, with or without
ﬁbroelastic proliferation and chronic inﬂammatory chan-
ges’’ [4].
Mechanics of the plantar fascia
Hicks described a windlass mechanism of action for the
plantar fascia. Dorsiﬂexion of the toes leads to a shortened
effective length of the plantar fascia causing a raising of
the arch. Toe extension leads to increased arch tension with
the metatarsophalangeal joint as the pivot or tethering
point. Hicks [5] demonstrated this deﬁnitively with
cadaveric models.
When a plantar fasciotomy was performed, the cadaver
would lose this windlass mechanism, thus diminishing the
arch stability subsequently disallowing a more stable ter-
minal stance and toe standing. In addition, Hicks [5] found
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3.4 times the subject’s body weight. Thus, the plantar
fascia, while playing a signiﬁcant role in walking stability,
can readily break with a minimal increase in strain.
While the exact etiology of plantar fasciitis remains
unclear, it is theorized that overloading the plantar foot
muscles originating at the volar calcaneus (adductor hal-
lucis, quadratus plantae, ﬂexor digitorum brevis, and
abductor digiti minimi quinti) can lead to inﬂammation and
consequent pain in the plantar fascia [6]. Hence, therapy
for plantar fasciitis focuses on either reducing the muscle
tightness that causes the initial injury or reducing the
inﬂammation that worsens the injury.
Diagnosis
Plantar fasciitis is a clinical diagnosis. It is based on
patient history and physical exam. Patients can present
with local point tenderness along the medial tuberosity of
the os calcis, pain on weight bearing and/or pain on ﬁrst
steps. Plantar fascia pain is especially evident upon dor-
siﬂexion of the patients pedal phalanges, which further
stretches the plantar fascia or windlass mechanism.
Therefore, any activity that would increase stretch of the
plantar fascia, such as walking barefoot without any arch
support, climbing stairs, or toe walking, can worsen the
pain [4, 7].
Fig. 1 From Buchbinder [4].
Used with permission from
NEJM. Plantar and medial
views of the foot demonstrating
the origin and insertion of the
plantar fascia and the location of
nerves in proximity to the heel.
The windlass mechanism, or
bowstring effect, of the plantar
fascia refers to its function in
raising the arch of the foot
during the push-off phase of
walking
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A Medline search from 1996 to the present was performed.
Trials were included if they were randomized studies and
evaluated orthoses, stretching, extracorporeal shockwave,
BTX-A, or corticosteroid injection as therapies for plantar
fasciitis. Trials were excluded if they did not meet the
above criteria or if they compared the efﬁcacy of one mode
of therapy to another, that is, stretching to orthoses or
BTX-A to steroid therapy in plantar fasciitis. According to
SORT grading of quality of evidence assessments [8], all
studies used were Level 1. Case studies, retrospective
studies, descriptive articles, and quasi-randomized studies
were excluded from the review; however, these studies
were included in the introduction and discussion sections
(Table 1).
Numerous treatment measures have been used for
plantar fasciitis with varied clinical beneﬁts. Nonsurgical
techniques include orthoses [9, 10], stretching [11–13],
splinting, taping, topical medications with or without
iontophoresis, oral nonsteroidal anti-inﬂammatory medi-
cations [22], extracorporeal shockwave therapy [14–18],
laser, and percutaneous injections with steroid [20, 21]o r
botulinum toxin type A. Surgical options with endoscopic
or open fasciotomy can be the last resort for patients with
intractable plantar fasciitis [23], but are not discussed
further in the article.
Orthoses
Landorf et al. described a participant blinded randomized
trial where they compared the response of 135 patients with
plantar fasciitis to soft thin foam sham orthoses, prefabri-
cated ﬁrm foam orthoses, and customized semi-rigid plastic
orthoses over 3 months. While they were able to show
statistically signiﬁcant results for improved function with
the prefabricated and customized orthoses as compared to
the sham, Landorf et al. [9] were unable to show statistical
signiﬁcance for improvements in pain and concluded that
both customized and prefabricated orthoses were efﬁca-
cious for the treatment of plantar fasciitis.
Winemiller et al. compared the response of 101
patients to active bipolar magnet cushioned insoles or
sham insoles over 8 weeks. They found that there was no
statistically signiﬁcant difference in improvement in
subjective heel pain between different insole modes;
however, there was a statistically signiﬁcant improvement
in both the magnetic and nonmagnetic groups in morning
foot pain intensity. Winemiller et al. [10] claimed that













Landorf et al. [9] 4 weeks 3 months Yes




DiGiovanni et al. [11] 10 months 8 weeks Yes
DiGiovanni et al. [12] 10 months 2 years Yes
Radford et al. [13] 4 weeks 2 weeks No
Extracorporeal shockwave therapy A Inconsistent
Haake et al. [14] 6 months 12 weeks, 1 year No
Speed et al. [15] 3 months 6 months No
Buchbinder et al. [16] 6 weeks 12 weeks No
Kudo et al. [17] 6 months 3 months Yes
Ogden et al. [18] N/A 3 months, 1 year Yes
BTX-A B Consistent
Babcock et al. [19] 6 months 3 weeks,
8 weeks
Yes
Steroid injection/iontophoresis A Consistent
Crawford et al. [20] N/A 1 month Yes
Gudeman et al. [21] N/A 2 weeks Yes
Note: All are Level 1 quality studies
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Stretch
DiGiovanni et al. assessed the role of Achilles tendon
stretching versus plantar fascia stretching in a randomized
study of 101 patients. Both Achilles stretching groups and
plantar fascia stretching groups appreciated a decrease in
pain upon ﬁrst steps in the morning as well as increased
function; however, the plantar stretchers appreciated a sta-
tistically signiﬁcant improvement in activity function and
ﬁrst step pain as compared to the Achilles stretchers [11].
DiGiovanni further assessed the improvement of plantar
fascia versus Achilles tendon stretching by directly com-
paring the two in a crossover study of the same patient pool
with a 2-year follow up. DiGiovanni et al. switched Achilles
tendon group to plantar fascia stretching after the initial
8 weeks of the trial. After 2 years, the Achilles tendon
patient pool was reassessed for maximum pain level and
pain on ﬁrst steps in the morning. While there was a sig-
niﬁcant difference between the two groups at 8 weeks, there
was no statistical difference between the two at 2 years,
with further improvement in pain in both groups [12].
Radford recruited 92 subjects for their study that com-
pared calf muscle stretching with sham ultrasound to sham
ultrasound alone. The study tested the short-term effec-
tiveness of stretching. In the 14 days that the study lasted,
there was no statistically signiﬁcant difference between
stretch and sham groups. Radford et al. concluded that
short-term stretching shows no statistically signiﬁcant
beneﬁt for plantar fasciitis [13].
Extracorporeal shockwave therapy
Haake et al. assessed the efﬁcacy of extracorporeal
shockwave therapy (ESWT) in 272 subjects. The patients
employed in this study had tried more conservative meth-
ods of plantar fasciitis therapy without effect for
approximately 6 months. The study pool either received
ESWT or sham therapy. The patients were assessed after
12 weeks. Haake et al. found that approximately three-
fourth of their study pool improved regardless of sham or
ESWT. Consequently, they showed that ESWT was
‘‘ineffective in the treatment of chronic plantar fasciitis’’
[14].
Speed studied 88 patients who had plantar fasciitis for at
least 3 months each. The patients were exposed to thera-
peutic sessions with sham or ESWT once every month for a
total of 3 months. Three effects were assessed: day pain,
night pain, and ‘‘morning startup pain.’’ The patients were
assessed at the beginning of the study, the beginning of the
treatment, and at 1 and 3 months after completion of the
treatment. Over the 6-month course of the study, no sta-
tistical signiﬁcance was shown between sham and ESWT
groups in the above categories [15].
Buchbinder et al. recruited 166 patients for their study
in which they used ultrasound guided ESWT on patients
who had plantar fasciitis for at least 6 weeks. Statistically
signiﬁcant improvements were appreciated in both the
placebo/sham groups and ESWT groups in morning step
pain, general activity pain, and overall pain characteriza-
tion. Buchbinder et al. [16] demonstrated that ESWT
provided no greater beneﬁt than placebo.
Kudo et al. performed a conﬁrmatory study in which
they compared ESWT to sham ESWT in 114 patients with
plantar fasciitis for at least 6 months and resistant to other
therapies. Patients were excluded from the study if they
had used other modes of therapy within 2 weeks of their
treatment. The patients were exposed to a single treatment.
This study demonstrated a statistically signiﬁcant
improvement in ﬁrst steps pain by visual analog scale at
3 months. Kudo et al. [17] reported that ESWT provides
for a beneﬁcial treatment in recalcitrant plantar fasciitis.
Ogden et al. found ESWT to be an effective treatment
for plantar fasciitis in their two phase trial. In the ﬁrst
phase, they formulated and ﬁnalized their protocol with 20
nonblinded patients. In the phase two trial, Ogden ran-
domized 293 patients to receive either ESWT and an ankle
block or a mild anesthetic and nontransmitted shockwaves.
They found signiﬁcant differences in investigator assess-
ment of heel pain at 4, 8, and 12 weeks and at 12 months
using a dolorimeter-based visual analog scale. Signiﬁcance
was also found in subjective self-assessment of morning
heel pain at the same time intervals. However, in self-
assessment of activity related pain, signiﬁcance could be
found at 4, 8, and 12 weeks, but not at 12 months. Hence,
Ogden et al. [18] were able to complete that ESWT shows
beneﬁcial response in plantar fasciitis up to and for at least
1 year.
Botulinum toxin type A (BTX-A)
Babcock et al. investigated 27 patients (43 plantar fasciae)
with duration of symptoms for at least 6 months. Either
BTX-A was injected into the feet of the therapy group or
saline into the sham group. In the case of patients with
bilateral plantar fasciitis, saline was injected into one foot
and BTX-A in the other. The authors showed that the BTX-
A groups had statistically signiﬁcant improvements at 3
and 8 weeks in all variables tested (Maryland foot score,
pain visual analog scale, pressure algometry response, and
pain relief visual analog scale). Babcock et al. [19]
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improves the patients pain level.
Steroid
Crawford et al. described 106 patients, which they divided
into four groups: prednisolone with lignocaine, predniso-
lone with lignocaine after a tibial block, lignocaine alone,
or lignocaine after a tibial block. There was no statistically
signiﬁcant difference in pain levels when prednisolone was
given with tibial block or when anesthetic was given. There
was a statistically signiﬁcant decrease in pain levels
according to visual analog scales in both groups of patients
receiving steroid after 1 month; however, after 3 months
there was no statistical signiﬁcant difference. Hence,
Crawford et al. [20] concluded that steroid injections can
provide short-term relief.
Gudeman assessed the efﬁcacy of steroid iontophoresis
in 40 feet (37 subjects). Feet were divided equally into a
group that received phosphate buffered solution iontopho-
resis and one that received dexamethasone iontophoresis.
The treatments lasted for 2 weeks during which each foot
received six iontophereses. The Maryland foot score was
used to analyze the groups. The active group showed sig-
niﬁcantly greater improvement immediately after
treatment. However, both groups showed positive results at
1 month follow up. Ultimately, Gudeman et al. [21] found
that dexamethasone iontophoresis is effective in improving
pain immediately after treatment, but not more than pla-
cebo in the longer term.
Discussion
As evidenced above, multiple modes of therapy can lead to
pain reduction in plantar fasciitis. Initial conservative
management provides satisfactory results in approximately
80–90% of cases in clinical practice [24–27]. When more
conservative management is unsuccessful, steroid injection
is a preferred option [28–30]. Although steroid injection is
the mainstay for the management of many hyper inﬂam-
matory disorders, there is little known about steroid affect at
the cellular level and, consequently, little about the etiology
of the risks of connective tissue rupture after the same [31].
Fascial rupture, which can be likened to tendon rupture,
was investigated by Kennedy and Willis, who found that
failing strengths decreased by 35% after administration of
steroid in vitro to Achilles tendons. Cystic spaces and col-
lagen necrosis were appreciated in their steroid group. This
result continued through to 7 days. However, at 2 and 4
weeks following injection, these cystic spaces were
replaced by an eosinophillic staining material and ﬁbroblast
proliferation was noted. Disordered collagen deposition was
appreciated under scanning electron microscope. In addi-
tion, the failing strength returned to that of the control
subjects. By 6 weeks, full biomechanical integrity was
reestablished as evidenced by reorganization of collagen
into parallel ﬁbers. Hence, Kennedy and Willis concluded
that physiologic dosed steroid injection weakens normal
tendons for up to 14 days through collagen necrosis. They
also recommend limited physical activity for the 2 weeks
following injection and against repeated injection [24].
Furthermore, Wong et al. [32] showed that glucocorti-
coids suppress cellular metabolism and collagen synthesis
in cultured human tenocytes and proteoglycan production
[31]. Proteoglycan synthesis has a role in extracellular
matrix and collagen matrix ﬁbrillinogenesis. Wong et al.
[31, 33] concluded that spontaneous rupture following
steroid injection may occur through suppression of pro-
teoglycan synthesis.
While steroid injection and iontophoresis can signiﬁ-
cantly improve foot pain in plantar fasciitis, the two
methods warrant further investigation. As evidenced by
Crawford and Gudeman, steroid therapy in plantar fasciitis
plays a signiﬁcant role in short-term therapy [20, 21].
However, a number of complications were noted including
plantar fascial rupture, plantar fat pad atrophy, lateral
plantar nerve injury secondary to injection, and calcaneal
osteomyelitis and in iontophoresis, burning of the under-
lying skin [21, 34–39].
Fascial rupture and fat pad atrophy are especially serious
complications as they can lead to intractable complications.
Fascial rupture interrupts the intrinsic windlass mechanism
of the foot and can promote further inﬂammation in the
surrounding tissue, thus promoting pain. In addition,
plantar fat pad atrophy diminishes subcalcaneal cushion-
ing, availing the plantar fascia to further insult and, hence,
more pain. Acevedo et al. appreciated symptomatic rupture
in approximately 10% of subjects. Their retrospective chart
review showed that approximately two-thirds of the
patients (29/44) developed sudden onset rupture with a
subsequent inability to weight bear, whereas one-third did
not have acute onset. All of the ruptured patients presented
with new additional symptoms including long arch pain,
lateral mid foot pain, and an exam showing decreased
windlass tension [35].
Treatment of plantar fasciitis rupture remains unclear.
Treatment options for the rupture are open surgical repair,
endoscopic repair, and nonoperative measures. Sellman
and Acevedo et al. demonstrated that 50% of symptomatic
ruptured plantar fasciitis patients have long-term compli-
cations [36]. Acevedo and Beskin [35] used a special
treatment protocol including a ‘‘boot brace’’ which was
beneﬁcial for expedited symptom improvement with a
switch to a stiff soled athletic shoe with an arch support
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those patients with intractable plantar fasciitis with reso-
lution of symptomology in 57% of the patients.
Because of the recent availability and facility of ultra-
sound (US) to improve needle placement accuracy and
conﬁrmatory magnetic resonance imaging (MRI) in clini-
cal practice, enhanced therapeutic response rates have been
reﬂected in some of the studies [29, 30, 35, 41]. Tsai et al.
described the objectivity of US-guided steroid injection to
plantar fascia by demonstrating a decrease in fascial
thickness and loss of hypoechogenicity. In addition, fol-
lowing single US-guided steroid injection, fat pad atrophy,
which was theorized to cause worsening pedal dynamics,
was not observed [30]. Heel fat pad inﬂammation and
degeneration may cause pain and can be misdiagnosed as
plantar fasciitis [42]. Further, MRI or US can be used to
make appropriate diagnoses, which is particularly impor-
tant for patients with chronic polyarthritis.
Nevertheless, these complications are uncommon and
preventable; rupture may occur without steroid injections
[35]. Paying special attention to history and physical
examination change can lend some clues to associated
complications. Monitoring sudden pain loss, change of
patient pain location, developing numbness, changes in
plantar fascial and fat pad thickness, edema, palpable
masses, asymmetric ﬂexible hammertoe deformities of the
2nd, 3rd, and 4th toes without nerve injury, and utilizing
US for follow ups and injection placement can help to
alleviate negative outcomes. Further, limiting the number
and frequency of steroid injections and educating patients
on reduction of aggressive physical activity during a
2-week post-injection period should be suggested [35].
Conclusion
Steroid therapy is a valuable adjunct to other therapy
measures, including plantar fascial stretching. However,
one should be cognizant that overuse of steroid injection
can lead to complications. US guidance should be utilized
to improve injection target and monitor soft tissue changes,
thus preventing complication.
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